uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 28,716 Shares of Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 28,716 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $50.02, for a total transaction of $1,436,374.32. Following the sale, the chief executive officer owned 519,227 shares in the company, valued at $25,971,734.54. The trade was a 5.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

QURE stock opened at $47.51 on Friday. The company’s 50-day moving average price is $27.84 and its two-hundred day moving average price is $23.02. The firm has a market cap of $3.00 billion, a P/E ratio of -13.65 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

QURE has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their price target on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Royal Bank Of Canada upped their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Thursday, June 18th. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Finally, Mizuho boosted their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Militia Capital Management LLC bought a new position in shares of uniQure in the 1st quarter valued at $1,540,000. Flax Pond Capital LLC grew its position in uniQure by 3.8% during the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock worth $2,486,000 after acquiring an additional 5,533 shares during the last quarter. Stempoint Capital LP grew its position in uniQure by 79.5% during the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 34,581 shares during the last quarter. Irenic Capital Management LP acquired a new position in uniQure in the 1st quarter worth about $1,635,000. Finally, Readystate Asset Management LP increased its holdings in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after purchasing an additional 143,142 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.